-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

Benzinga·05/14/2026 18:19:35
Listen to the news
JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.